证券代码：688319 证券简称：欧林生物 公告编号：2025-044 成都欧林生物科技股份有限公司关于持股 5%以上股 东权益变动触及 1%刻度的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 权益变动方向 比例增加□ 比例减少√ 权益变动前合计比例 29.22% 权益变动后合计比例 29.00% 本次变动是否违反已作出的承 是□ 否√ 诺、意向、计划 是否触发强制要约收购义务 是□ 否√ 一、 信息披露义务人及其一致行动人的基本信息 √控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 投资者及其一致行动人的身份 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他______________（请注明） 信息披露义务人名称 投资者身份 统一社会信用代码 √控股股东/实控人 上海武山生物技术有 □ 控股股东/实控人的一致 √915001036939216618 限公司 行动人 □ 不适用 □ 其他直接持股股东 一致行动人名称 投资者身份 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-044 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少√ | | --- | --- | --- | --- | | 权益变动前合计比例 | 29.22% | | | | 权益变动后合计比例 | 29.00% | | | | 本次变动是否违反已作出的承 | 是□ | 否√ | | | 诺、意向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否√ | | 一、 信息披露义务人及其一致行动人的基本信息 成都欧林生物科技股份有限公司关于持股 5%以上股 东权益变动触及 1%刻度的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1.身份类别 | | √控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他__ ...

Core Viewpoint - The company, Olin Bio (688319.SH), has decided to terminate its planned private placement of shares due to current market conditions and internal assessments, despite the ongoing progress of its vaccine research and production base technology renovation project [1][2]. Group 1: Company Overview - Olin Bio is headquartered in Chengdu and has three core products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine, with the Tetanus Toxoid Vaccine maintaining a leading market share in China [1]. - The company has a GMP base of approximately 80,000 square meters, which includes three bulk production lines, four filling lines, two packaging lines, one R&D center, one quality inspection center, and one experimental animal center [1]. Group 2: Fundraising and Financials - The planned private placement aimed to raise 175 million yuan for the technology renovation project, which has a total investment of approximately 290 million yuan [2]. - As of the first half of 2025, Olin Bio reported cash and cash equivalents of 184 million yuan and total liabilities of 902 million yuan, indicating potential cash flow pressure if the technology renovation project proceeds without the planned fundraising [2]. Group 3: Market Reaction and Stock Performance - Following the announcement of the private placement, Olin Bio's stock price surged from 16.17 yuan on June 17 to 28.87 yuan by September 2, representing an increase of over 78% [3]. - The company’s significant stock price increase raised concerns among investors about potential market overheating, especially as the private placement price was set significantly lower than the current market price [3][2]. Group 4: Shareholder Actions - Shortly after the private placement announcement, the controlling shareholder, Shanghai Wushan Biotechnology Co., Ltd., announced a plan to reduce its holdings by up to 12.18 million shares, representing no more than 3% of the company's total share capital [4].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. has decided to terminate its plan for a simplified procedure to issue shares to specific targets due to current market conditions and company circumstances, stating that this decision will not adversely affect its daily operations or shareholder interests [1][2]. Company Overview - Olin Biological primarily engages in the research, production, and sales of human vaccines, with key products including adsorbed tetanus vaccine, Hib conjugate vaccine, and AC conjugate vaccine, which are the main sources of revenue and cash flow [3]. Financial Performance - In the first half of 2025, Olin Biological achieved operating revenue of 306 million yuan, a year-on-year increase of 35.17%, and net profit attributable to shareholders of 13.2 million yuan, marking a turnaround from losses [3]. - As of June 30, 2025, the company reported total assets of 1.836 billion yuan, a 1.62% increase from the beginning of the year, with total liabilities of 902 million yuan, reflecting a 3.24% increase [3]. Fundraising and Investment Plans - The initial plan for the share issuance aimed to raise 175 million yuan to invest in the vaccine research and production base renovation project, which has a total investment of 290 million yuan [2]. - The project was intended to upgrade production facilities for various vaccine products, thereby optimizing production processes and expanding product lines [2].

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]

Core Viewpoint - 欧林生物 has decided to terminate its plan for a simplified procedure to issue A-shares to specific investors and has withdrawn the application due to current market conditions and company circumstances [1] Group 1: Termination of Share Issuance - The company held its seventh board meeting on August 29, 2025, where it approved the termination of the A-share issuance plan [1] - The decision was made after careful analysis of various factors, including market conditions and the company's development plans [1] - The termination of the share issuance will not significantly impact the company's daily operations or harm the interests of the company and its shareholders [1] Group 2: Previous Issuance Plan Details - The previous plan aimed to raise up to RMB 300 million, with a maximum of 20% of the company's net assets from the previous year [2] - The funds were intended for the vaccine research and production base renovation project, with a total investment of RMB 290 million [3] - The planned issuance involved 9,138,795 shares at a price of RMB 13.71 per share, representing up to 30% of the company's total share capital before the issuance [4] Group 3: Shareholder Structure and Control - Shanghai Wushan is the controlling shareholder, holding 17.83% of the company's shares, while the actual controllers are 樊绍文 and 樊钒, who collectively control 29.22% of the voting rights [5] - After the planned issuance, the actual controllers would hold 28.58% of the voting rights, indicating no change in control [5] Group 4: Acquisition of Minority Stake - The company plans to acquire a total of 15% of the minority shares in its subsidiary, 新诺明生物, through a public transfer at a price not exceeding RMB 45 million [6] - This acquisition does not constitute a major asset restructuring and does not involve related transactions [6]

中芯国际涨6.67%，华虹半导体涨超5%，英诺赛科涨1.68%，上海复旦涨0.99%。 (本文来自第一财经) ...

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688319 证券简称：欧林生物 公告编号：2025-042 成都欧林生物科技股份有限公司 关于终止本次以简易程序向特定对象 发行人民币普通股 （A股）股票事项并撤回申请文件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 成都欧林生物科技股份有限公司（以下简称"公司"）于2025年8月29日召开第七届董事会第四次会议， 审议通过了《关于终止以简易程序向特定对象发行A股股票事项并撤回申请文件的议案》。现将相关事 项公告如下： 一、公司本次以简易程序向特定对象发行股票的基本情况 1、2024年4月24日，公司第六届董事会第十五次会议审议通过了《关于提请公司股东大会授权董事会以 简易程序向特定对象发行股票并办理相关事宜的议案》。 2、2024年5月17日，公司2023年年度股东大会审议通过《关于提请公司股东大会授权董事会以简易程序 向特定对象发行股票并办理相关事宜的议案》，授权公司董事会在相关法律、法规、规范性文件以及 《公司章程》的范围内全权办理与本次以简易程 ...

Mergers and Acquisitions - Huahong Company plans to acquire 97.5% equity of Huali Microelectronics through a combination of issuing shares and cash payment, raising supporting funds [1] - Olin Bio intends to acquire 15% equity of Xinnuo Ming Bio from minority shareholders via public transfer at a price not exceeding 45 million yuan [2] - Dongxin Co. plans to invest approximately 211 million yuan in Shanghai Lishuan, holding about 35.87% equity post-investment [3] Shareholding Changes - Gao Neng Environment's controlling shareholder plans to reduce holdings by up to 3%, equating to a maximum cash-out of 320 million yuan [4][5] - Hu Dian Co.'s senior management intends to reduce holdings by up to 16,040 shares, representing about 0.0083% of total equity [6] - Maike Audi's shareholders have collectively reduced their holdings by 2.17%, with specific reductions of 5.41 million shares and 5.86 million shares [7] Risk Matters - *ST Tianmao plans to voluntarily withdraw its A-share listing and will initiate a protection mechanism for dissenting shareholders [8] - China Rare Earth confirms no undisclosed matters that could affect stock trading prices amid unusual trading fluctuations [9] Lock-up Release - Suda Co. announces that approximately 27.94 million shares will be released from lock-up on September 3, 2025, accounting for 36.76% of total equity [10]